COMMUNIQUÉS West-GlobeNewswire

-
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
22/10/2025 -
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
22/10/2025 -
ADARx Pharmaceuticals Announces First Patient Dosed in Phase 3 STOP-HAE Clinical Trial and Orphan Drug Designation for ADX-324, a Long-Acting siRNA in Development for the Prophylactic Treatment of Hereditary Angioedema (HAE)
22/10/2025 -
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment
22/10/2025 -
Akari Therapeutics Announces Launch of CEO Corner Platform
22/10/2025 -
Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause
22/10/2025 -
BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
22/10/2025 -
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
22/10/2025 -
Branded Legacy, Inc. (OTC: BLEG) Advances Life-Saving Innovation with FDA Pre-ANDA Briefing for Revolutionary Intranasal Naloxone Spray
22/10/2025 -
Fangzhou Unveils “AI + Weight Management” Innovation at China’s Inaugural National-Level Weight Management Symposium in Beijing
22/10/2025 -
UFC® and Smith+Nephew announce multi-year extension of partnership
22/10/2025 -
L'usine de médicaments stériles Curia nommée fabricant de l'année dans le Massachusetts
22/10/2025 -
ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 50 Million
22/10/2025 -
Back to Life with Resuscitec’s CARL® Groundbreaking ECPR System – Nominated for the Prix Galien USA 2025 Award
22/10/2025 -
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
22/10/2025 -
Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital
22/10/2025 -
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
22/10/2025 -
Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
22/10/2025 -
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
22/10/2025
Pages